Skip to content

Study · Systematic review · 2021

10 results

Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?

Updike WH, Pane O, Franks R, Saber F, Abdeen F, Balazy DD, Carris NW

Drugs30 Apr 2021Cited by 19 (Europe PMC)

PMID33929717 (opens in a new tab)DOI10.1007/s40265-021-01525-x (opens in a new tab)PepBankPUB-33929717
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In overweight adults, weight loss with liraglutide 1.8 mg daily was sufficient in one trial.

    In plain wordsIn overweight adults, liraglutide 1.8 mg daily produced enough weight loss in one trial.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss with liraglutide 1.8 mg daily
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg dailyAs given in this study (human).

    Source sentences

    Summary
    Weight loss was sufficient with liraglutide 1.8 mg daily in one trial
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.
  2. 02HumanSystematic reviewEfficacy outcome

    In overweight adults, weight loss with liraglutide 3.0 mg daily was consistently sufficient.

    In plain wordsIn overweight adults, liraglutide 3.0 mg daily consistently produced enough weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss with liraglutide 3.0 mg daily
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg dailyAs given in this study (human).

    Source sentences

    Summary
    and was consistently sufficient with liraglutide 3.0 mg daily.
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.
  3. 03HumanSystematic reviewEfficacy outcome

    In overweight adults, oral and injectable semaglutide at both doses consistently produced weight loss.

    In plain wordsIn overweight adults, oral and injectable semaglutide at both doses consistently led to weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss with oral and injectable semaglutide
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral and injectableAs given in this study (human).

    Source sentences

    Summary
    Oral and injectable semaglutide at both doses consistently produced weight loss
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.
  4. 04HumanSystematic reviewSafety outcome

    In overweight adults, oral and injectable semaglutide demonstrated a potential increased risk for retinopathy.

    In plain wordsIn overweight adults, semaglutide showed a possible higher risk of eye damage (retinopathy).

    Peptide
    Semaglutide
    Outcome
    IncreaseRetinopathy risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated · oral and injectableAs given in this study (human).

    Source sentences

    Summary
    though demonstrated a potential increased risk for retinopathy.
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In overweight adults, pooled GLP1-RAs (including liraglutide) consistently produced weight loss across 20 phase III trials.

    In plain wordsIn overweight adults, the GLP-1 drug class, including liraglutide, was linked to weight loss across 20 phase III trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The GLP1-RAs consistently produced weight loss.
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In overweight adults, pooled GLP1-RAs (including semaglutide) consistently produced weight loss across 20 phase III trials.

    In plain wordsIn overweight adults, the GLP-1 drug class, including semaglutide, was linked to weight loss across 20 phase III trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The GLP1-RAs consistently produced weight loss.
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Pooled GLP1-RAs (including liraglutide) carried a generally low hypoglycemia risk without other precipitating factors.

    In plain wordsThe GLP-1 drug class, including liraglutide, generally carried a low risk of low blood sugar without other triggers.

    Peptide
    Liraglutide
    Outcome
    Not applicableHypoglycemia risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Hypoglycemia risk with GLP1-RAs was generally low without other precipitating factors
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Pooled GLP1-RAs (including semaglutide) carried a generally low hypoglycemia risk without other precipitating factors.

    In plain wordsThe GLP-1 drug class, including semaglutide, generally carried a low risk of low blood sugar without other triggers.

    Peptide
    Semaglutide
    Outcome
    Not applicableHypoglycemia risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Hypoglycemia risk with GLP1-RAs was generally low without other precipitating factors
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Gastrointestinal adverse effects were common with pooled GLP1-RAs (including liraglutide).

    In plain wordsStomach and gut side effects were common with the GLP-1 drug class, including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastrointestinal adverse effects
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    whereas gastrointestinal adverse effects were common.
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Gastrointestinal adverse effects were common with pooled GLP1-RAs (including semaglutide).

    In plain wordsStomach and gut side effects were common with the GLP-1 drug class, including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal adverse effects
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    whereas gastrointestinal adverse effects were common.
    2 context sentences
    Summary · context
    Therefore, we assessed whether GLP1-RAs warrant use in patients who are overweight (body mass index 27.0-29.9 kg/m2) without weight-related comorbidity.
    Summary · context
    We assessed 20 phase III trials of GLP1-RAs studied in cardiovascular outcome trials.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.